Correlation Between NYSE Composite and Salarius Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both NYSE Composite and Salarius Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NYSE Composite and Salarius Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between NYSE Composite and Salarius Pharmaceuticals, you can compare the effects of market volatilities on NYSE Composite and Salarius Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NYSE Composite with a short position of Salarius Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of NYSE Composite and Salarius Pharmaceuticals.
Diversification Opportunities for NYSE Composite and Salarius Pharmaceuticals
-0.18 | Correlation Coefficient |
Good diversification
The 3 months correlation between NYSE and Salarius is -0.18. Overlapping area represents the amount of risk that can be diversified away by holding NYSE Composite and Salarius Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Salarius Pharmaceuticals and NYSE Composite is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NYSE Composite are associated (or correlated) with Salarius Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Salarius Pharmaceuticals has no effect on the direction of NYSE Composite i.e., NYSE Composite and Salarius Pharmaceuticals go up and down completely randomly.
Pair Corralation between NYSE Composite and Salarius Pharmaceuticals
Assuming the 90 days trading horizon NYSE Composite is expected to generate 0.07 times more return on investment than Salarius Pharmaceuticals. However, NYSE Composite is 13.69 times less risky than Salarius Pharmaceuticals. It trades about 0.17 of its potential returns per unit of risk. Salarius Pharmaceuticals is currently generating about -0.02 per unit of risk. If you would invest 1,482,589 in NYSE Composite on August 25, 2024 and sell it today you would earn a total of 529,756 from holding NYSE Composite or generate 35.73% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
NYSE Composite vs. Salarius Pharmaceuticals
Performance |
| Timeline |
NYSE Composite and Salarius Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
NYSE Composite
Pair trading matchups for NYSE Composite
Salarius Pharmaceuticals
Pair trading matchups for Salarius Pharmaceuticals
Pair Trading with NYSE Composite and Salarius Pharmaceuticals
The main advantage of trading using opposite NYSE Composite and Salarius Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NYSE Composite position performs unexpectedly, Salarius Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Salarius Pharmaceuticals will offset losses from the drop in Salarius Pharmaceuticals' long position.| NYSE Composite vs. Glacier Bancorp | NYSE Composite vs. LithiumBank Resources Corp | NYSE Composite vs. Stepstone Group | NYSE Composite vs. Pintec Technology Holdings |
| Salarius Pharmaceuticals vs. Akari Therapeutics PLC | Salarius Pharmaceuticals vs. Histogen | Salarius Pharmaceuticals vs. Nutriband | Salarius Pharmaceuticals vs. Aileron Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Complementary Tools
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |